Further consequences of SLC7A11 overexpression entail resistance to geldanamycin in lung cancer, temozolomide in glioblastoma, and gemcitabine in pancreatic cancer [47,234, 235]. This evidence concerns the gene SLC7A11 and glioblastoma.